TR200806258T2 - Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler - Google Patents

Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler

Info

Publication number
TR200806258T2
TR200806258T2 TR2008/06258T TR200806258T TR200806258T2 TR 200806258 T2 TR200806258 T2 TR 200806258T2 TR 2008/06258 T TR2008/06258 T TR 2008/06258T TR 200806258 T TR200806258 T TR 200806258T TR 200806258 T2 TR200806258 T2 TR 200806258T2
Authority
TR
Turkey
Prior art keywords
tuberculosis
compounds
diagnosis
methods
immunotherapy
Prior art date
Application number
TR2008/06258T
Other languages
English (en)
Inventor
G Reed Steven
A. W. Skeiky Yasir
C Dillon Davin
R Twardzik Daniel
Houghton Raymond
H Vedvick Thomas
Campos-Neto Antonio
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200806258(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of TR200806258T2 publication Critical patent/TR200806258T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tüberküloza karşı koruyucu bağışıklık sağlayan bileşikler ve yöntemler açıklanmaktadır. Sağlanan bileşikler bir ya da daha fazla Af. tuberculosis proteininin en az bir immünojenik kısmını içeren polipeptidleri ve böyle polipeptidleri kodlayan DNA moleküllerini ihtiva etmektedir. Böyle bileşikler Af. tuberculosis enfeksiyonuna karşı bağışıklık sağlayan aşılar ve/veya farmasötik kompozisyonlar halinde formüle edilebilmekte ve tüberkülozun teşhisi için kullanılabilmektedir.
TR2008/06258T 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler TR200806258T2 (tr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52343695A 1995-09-01 1995-09-01
US53363495A 1995-09-22 1995-09-22
US62087496A 1996-03-22 1996-03-22
US65968396A 1996-06-05 1996-06-05
US68057496A 1996-07-12 1996-07-12

Publications (1)

Publication Number Publication Date
TR200806258T2 true TR200806258T2 (tr) 2008-10-21

Family

ID=27541835

Family Applications (5)

Application Number Title Priority Date Filing Date
TR2009/01109T TR200901109T1 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
TR1998/00411T TR199800411T1 (tr) 1995-09-01 1996-08-30 Tüberkülozun teshisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bilesikler.
TR2008/06259T TR200806259T2 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
TR2008/06258T TR200806258T2 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
TR2004/03064T TR200403064T2 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
TR2009/01109T TR200901109T1 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
TR1998/00411T TR199800411T1 (tr) 1995-09-01 1996-08-30 Tüberkülozun teshisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bilesikler.
TR2008/06259T TR200806259T2 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2004/03064T TR200403064T2 (tr) 1995-09-01 1996-08-30 Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler.

Country Status (23)

Country Link
EP (5) EP1398379B1 (tr)
JP (5) JP4382160B2 (tr)
KR (1) KR100433750B1 (tr)
CN (1) CN1117149C (tr)
AT (5) ATE323165T1 (tr)
AU (1) AU727602B2 (tr)
BR (2) BR9610262B1 (tr)
CA (3) CA2653566C (tr)
CY (2) CY2570B1 (tr)
CZ (3) CZ300688B6 (tr)
DE (4) DE69637879D1 (tr)
DK (4) DK1203817T3 (tr)
ES (4) ES2262595T3 (tr)
HU (2) HU227778B1 (tr)
IL (1) IL123506A (tr)
MX (1) MX9801638A (tr)
NO (4) NO324372B1 (tr)
NZ (1) NZ319377A (tr)
PL (1) PL186774B1 (tr)
PT (4) PT1398379E (tr)
SI (1) SI0851927T1 (tr)
TR (5) TR200901109T1 (tr)
WO (1) WO1997009428A2 (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2501135Y2 (ja) 1989-06-10 1996-06-12 エヌティエヌ株式会社 摩擦式無段変速機
JP2501911B2 (ja) 1989-08-15 1996-05-29 日産自動車株式会社 トロイダル型無段変速機
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
BR9712298A (pt) * 1996-10-11 2000-10-24 Corixa Corp Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
ATE370236T1 (de) * 1997-04-02 2007-09-15 Statens Seruminstitut Nukleinsäure- und polypeptidfragmente von m. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
EP1003870A1 (en) * 1997-07-16 2000-05-31 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
CA2319380A1 (en) * 1997-11-10 1999-05-20 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from m. tuberculosis
EP1484405A1 (en) * 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
GB9808720D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP2087906A1 (en) 1999-05-04 2009-08-12 The University of Medicine and Dentistry of New Jersey Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
FI119445B (fi) * 2004-10-29 2008-11-14 Waertsilae Finland Oy Polttomoottorin polttoaineen syöttöjärjestelmän paineen värähtelyn vaimennin
CN102220357B (zh) 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
FR2952058B1 (fr) * 2009-10-29 2013-10-04 Centre Nat Rech Scient Procede de ligation native de polypeptides
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
FR2971509B1 (fr) * 2011-02-16 2013-02-22 Centre Nat Rech Scient Procede de preparation de peptides par assemblage de multiples fragments peptidiques
CN103290030A (zh) * 2012-02-23 2013-09-11 上海交通大学 一种结核分枝杆菌标志物HtdY的重组蛋白及其制备方法和临床应用
RU2737765C2 (ru) * 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US20170121377A1 (en) * 2014-04-04 2017-05-04 Vestaron Corporation Artificially activated toxic peptides
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
FR3048286B1 (fr) * 2016-02-26 2021-01-22 Omunis Peptides immunogenes et leur utilisation
CN107304231B (zh) * 2016-04-18 2021-01-01 华中农业大学 一种结核分枝杆菌融合蛋白及应用
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244539A1 (en) * 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) * 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
FR2677365B1 (fr) * 1991-06-07 1995-08-04 Pasteur Institut Proteines de mycobacterium et applications.
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine

Also Published As

Publication number Publication date
SI0851927T1 (en) 2004-02-29
IL123506A (en) 2004-12-15
EP1398379A2 (en) 2004-03-17
PT1398379E (pt) 2007-01-31
CZ297406B6 (cs) 2006-12-13
EP1347055A2 (en) 2003-09-24
JP4324597B2 (ja) 2009-09-02
JP4382160B2 (ja) 2009-12-09
NO20070621L (no) 1998-04-27
CZ300688B6 (cs) 2009-07-15
CY2612B2 (en) 2010-12-22
EP1347055A3 (en) 2003-11-26
HU227778B1 (en) 2012-02-28
DK1347055T3 (da) 2009-06-29
NO336288B1 (no) 2015-07-13
EP1203817B9 (en) 2006-08-16
CA2230885A1 (en) 1997-03-13
EP1203817A2 (en) 2002-05-08
JP2009159982A (ja) 2009-07-23
DE69630457T2 (de) 2004-11-25
NZ319377A (en) 2000-01-28
PL186774B1 (pl) 2004-02-27
CA2684425A1 (en) 1997-03-13
TR200901109T1 (tr) 2012-02-21
NO20070619L (no) 1998-04-27
NO324372B1 (no) 2007-10-01
PT1347055E (pt) 2009-06-19
KR19990044347A (ko) 1999-06-25
ATE337399T1 (de) 2006-09-15
BR9612997B1 (pt) 2012-01-10
JP4324618B2 (ja) 2009-09-02
JP4324596B2 (ja) 2009-09-02
WO1997009428A3 (en) 1997-07-17
DE69630457D1 (de) 2003-11-27
PT851927E (pt) 2004-03-31
EP1347055B1 (en) 2009-03-18
EP0851927A2 (en) 1998-07-08
BR9610262B1 (pt) 2013-11-26
JP2006187292A (ja) 2006-07-20
EP0851927B1 (en) 2003-10-22
ES2210392T3 (es) 2004-07-01
ATE426025T1 (de) 2009-04-15
TR200403064T2 (tr) 2005-08-22
AU727602B2 (en) 2000-12-14
EP1712628A2 (en) 2006-10-18
CY2570B1 (en) 2008-07-02
KR100433750B1 (ko) 2004-09-01
DE69637879D1 (de) 2009-04-30
BR9610262A (pt) 1999-07-06
ES2271449T3 (es) 2007-04-16
DK1398379T3 (da) 2007-01-08
IL123506A0 (en) 1998-10-30
EP1203817A3 (en) 2003-01-29
EP1712628A3 (en) 2007-05-23
JP2007228972A (ja) 2007-09-13
HUP9900902A3 (en) 2001-03-28
MX9801638A (es) 1998-05-31
PT1203817E (pt) 2006-08-31
DE69636487D1 (de) 2006-10-05
NO20070618L (no) 1998-04-27
DE69636487T2 (de) 2007-05-03
EP1712628B1 (en) 2011-06-22
CZ62898A3 (cs) 1999-10-13
CA2653566C (en) 2013-06-25
CN1200147A (zh) 1998-11-25
DK0851927T3 (da) 2004-01-26
DK1203817T3 (da) 2006-08-14
HK1059282A1 (en) 2004-06-25
PL325373A1 (en) 1998-07-20
DE69636046T2 (de) 2006-11-23
CN1117149C (zh) 2003-08-06
NO980883D0 (no) 1998-02-27
ATE252640T1 (de) 2003-11-15
ATE323165T1 (de) 2006-04-15
CZ300953B6 (cs) 2009-09-23
ES2324529T3 (es) 2009-08-10
CA2653566A1 (en) 1997-03-13
DE69636046D1 (de) 2006-05-24
HUP9900902A2 (hu) 1999-07-28
EP1398379B1 (en) 2006-08-23
JP2006149406A (ja) 2006-06-15
EP1203817B1 (en) 2006-04-12
WO1997009428A2 (en) 1997-03-13
EP1398379A3 (en) 2004-07-14
JP2001517069A (ja) 2001-10-02
CA2230885C (en) 2010-02-02
HU225979B1 (en) 2008-02-28
TR199800411T1 (tr) 1998-05-21
TR200806259T2 (tr) 2008-10-21
AU7158696A (en) 1997-03-27
ATE513915T1 (de) 2011-07-15
NO980883L (no) 1998-04-27
ES2262595T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
TR200806258T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
TR200000115T2 (tr) Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler.
TR199901571T2 (tr) Tüberkülozun immünoterapi teshisi için bilesikler ve yöntemler.
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
WO2002024739A3 (en) Spas-1 cancer antigen
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium